Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BIO Vaccine Indemnification Proposal Would Require Govt. To Defend Suits

Executive Summary

The Biotechnology Industry Organization's indemnification proposal would require the government to defend against claims arising from potential adverse effects of bioterrorism vaccines

You may also be interested in...



Vaccine Definition Refined In Homeland Security Bill To Include Thimerosal

Vaccines are defined as including all components and ingredients listed in product license applications under the Homeland Security Act

Vaccine Definition Refined In Homeland Security Bill To Include Thimerosal

Vaccines are defined as including all components and ingredients listed in product license applications under the Homeland Security Act

Bioterror Patent Extensions Offered To Big Firms Under Revised Lieberman Bill

Large biotech firms producing counterterrorism measures could receive a two-year extension of a patent for another product under legislation introduced by Sen. Joseph Lieberman (D-Conn.)

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS038849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel